Recent Updates — TNXP
Tonix Pharmaceuticals Holding Corp. disclosed preliminary operating results for the quarter ended September 30, 2026. The company estimated net revenue from its product TONMYA to be between $14.0 million and $15.0 million. As of the end of the quarter, Tonix reported cash and cash equivalents of approximately $162.8 million. These figures are preliminary estimates subject to revision upon completion of financial closing procedures and should not be regarded as a representation of actual results. Tonix Pharmaceuticals Holding Corp. operates in the biopharmaceutical industry, focusing on the development and commercialization of immunotherapies.
Tonix Pharmaceuticals Holding Corp. received notice that Dr. Reddy’s Laboratories Ltd. filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV patent certification for a generic version of TONMYA (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg. The filing challenges four U.S. patents listed in the FDA Orange Book. Under federal law, this triggers a potential 30-month stay on FDA approval of the generic application if Tonix initiates patent infringement litigation within 45 days. Tonix intends to vigorously enforce its intellectual property rights but cannot predict the outcome of any resulting litigation or guarantee the validity of its patents. The company operates in the pharmaceutical industry, developing and commercializing treatments for central nervous system disorders.
Tonix Pharmaceuticals Holding Corp. announced a new managed Medicare payer agreement for its fibromyalgia treatment TONMYA, effective immediately. This addition covers approximately 21 million beneficiaries, bringing total Medicare coverage to 32 million lives (58% of U.S. Medicare). Combined with commercial and government payers, total coverage now reaches approximately 166 million individuals (53% of the U.S. population). The company also reported that its sales force has expanded to 150 representatives following the activation of 50 new hires. Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system disorders, infectious diseases, and immunology conditions.
Tonix Pharmaceuticals Holding Corp. announced on September 8, 2026, the promotion of Thomas Englese to Chief Commercial Officer, effective immediately. Mr. Englese previously served as Executive Vice President, Commercial Operations since September 2024 and will continue directing sales, marketing, market access, and commercial operations for TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, as well as Zembrace SymTouch and Tosymra for acute migraine. Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system disorders, infectious diseases, and immunology conditions.
On August 18, 2026, Tonix Pharmaceuticals Holding Corp. appointed President and CEO Dr. Seth Lederman as Interim Chief Medical Officer. Dr. Lederman will continue serving in his existing roles as President, CEO, and Chairman of the Board. This appointment is an internal administrative change with no impact on corporate strategy or financial condition. Tonix Pharmaceuticals Holding Corp. operates in the biopharmaceutical industry, focusing on the development of immunotherapies for autoimmune diseases.
Tonix Pharmaceuticals Holding Corp. reported second quarter 2026 operating results, announcing net product revenue of approximately $13.5 million, a significant increase from $2.0 million in the prior year period. Net sales of its flagship fibromyalgia treatment TONMYA totaled approximately $11 million, reflecting a 197% quarter-over-quarter growth driven by expanded payer coverage reaching 136 million covered lives and prescription volume doubling to 12,592 units. The company reported a net loss of $40.6 million, or $2.44 per share, compared to a $28.3 million loss in the same period last year, as R&D and SG&A expenses rose due to commercial launch investments and clinical trial costs. Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents.